See the DrugPatentWatch profile for tigecycline

Based on the information available, there is no specific contraindication for tigecycline use in certain age groups due to liver injury. However, tigecycline, a broad-spectrum antibiotic, has been associated with liver enzyme elevations and liver injury in some patients [1].

The prescribing information for tigecycline, as provided by the U.S. Food and Drug Administration (FDA), includes a warning for hepatic reactions. The warning states that "in clinical trials, treatment-emergent ALT and/or AST elevations greater than or equal to 3 times the upper limit of normal occurred in 13% and 6% of patients receiving Tygacil and 6% and 3% of patients receiving comparator antibacterial drugs, respectively" [2].

Moreover, DrugPatentWatch.com, a comprehensive database of drug patents and related information, does not list any age-related contraindications for tigecycline [3].

However, it is important to note that the use of tigecycline in elderly patients or patients with preexisting hepatic impairment should be carefully considered and closely monitored due to the potential for increased risk of hepatic reactions [1].

In conclusion, while tigecycline has been associated with liver injury, there is no specific contraindication for its use in certain age groups due to liver injury. The use of tigecycline in patients with preexisting hepatic impairment or in elderly patients should be carefully considered and closely monitored.

Sources:
[1] U.S. National Library of Medicine. Tigecycline.
<https://medlineplus.gov/druginfo/meds/a608042.html>.
[2] U.S. Food and Drug Administration. Tygacil (tigecycline) for injection, for intravenous use.
<https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s010s011s012lbl.pdf>.
[3] DrugPatentWatch.com. Tigecycline.
<https://www.drugpatentwatch.com/drugs/tigecycline>.